Abstract
The term scleritis describes a chronic inflammation that involves the outermost coat and skeleton of the eye. Disease can be isolated to the eye, but in up to half of affected individuals it occurs in the context of an immune-mediated systemic inflammatory condition, such as rheumatoid arthritis or Wegener's granulomatosis. Although uncommon, scleritis is often extremely painful, can lead to vision-threatening complications (and involvement of other ocular tissues), and is considered to confer an increased risk of mortality in patients with rheumatoid arthritis. Pathogenic mechanisms in scleritis are poorly understood, but enzymatic degradation of collagen fibrils by resident cells and infiltrating leukocytes seems to be a key feature. Several forms of inflammation can be distinguished histologically; interestingly, although the disease typically presents with engorgement of scleral vessels, vasculitis is not universally present at the microscopic level. Although some patients with scleritis respond well to treatment with NSAIDs, aggressive systemic therapy is often required to obtain a favorable outcome, particularly when systemic disease coexists. The mainstay of treatment is oral prednisone, but this agent is usually combined with a steroid-sparing immunosuppressive drug. New therapies presently under investigation for scleritis include local corticosteroid injections and various biologic agents.
Key Points
-
The hallmark symptom of scleritis is pain; examination of the eye typically reveals ocular redness due to engorged scleral vessels
-
Classification of scleritis into clinical subtypes is helpful to guide management, and predict both prognosis and the presence of associated systemic disease
-
Anterior scleritis, which is much more common than posterior scleritis, must be differentiated from other forms of 'red eye', such as conjunctivitis, episcleritis, corneal abrasions or ulcerations, acute anterior uveitis, and acute angle-closure glaucoma
-
Most cases of scleritis are immune-mediated, and in up to a half of patients a systemic disease (such as rheumatoid arthritis or Wegener's granulomatosis) coexists with the eye condition
-
Patients with non-necrotizing forms of scleritis might respond to prompt treatment with oral NSAIDs; if the scleritis does not improve, or when the inflammation is necrotizing or associated with a systemic vasculitis, more aggressive treatment than NSAID therapy with prednisone and/or corticosteroid-sparing agents is necessary
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akpek EK et al. (2004) Evaluation of patients with scleritis for systemic disease. Ophthalmology 111: 501–506
Tuft SJ and Watson PG (1991) Progression of scleral disease. Ophthalmology 98: 467–471
Sainz de la Maza M et al. (1994) Severity of scleritis and episcleritis. Ophthalmology 101: 389–396
McGavin DD et al. (1976) Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol 60: 192–226
Jayson MI and Jones DE (1971) Scleritis and rheumatoid arthritis. Ann Rheum Dis 30: 343–347
Smith JL (1957) Ocular complications of rheumatic fever and rheumatoid arthritis. Am J Ophthalmol 43 (Pt 1): 575–582
Watson PG et al. (1968) Episcleritis and scleritis. I. Br J Ophthalmol 52: 278–279
Watson PG and Hayreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol 60: 163–191
Watson PG (1980) The diagnosis and management of scleritis. Ophthalmology 87: 716–720
Sainz de la Maza M et al. (1994) Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases. Ophthalmology 101: 1281–1286
McCluskey PJ et al. (1999) Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 106: 2380–2386
Jabs DA et al. (2000) Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 130: 469–476
Sainz de la Maza M et al. (1995) Scleritis associated with systemic vasculitic diseases. Ophthalmology 102: 687–692
Hemady R et al. (1992) Six cases of scleritis associated with systemic infection. Am J Ophthalmol 114: 55–62
Livir-Rallatos C et al. (1998) Recurrent nodular scleritis associated with varicella zoster virus. Am J Ophthalmol 126: 594–597
Lee GA et al. (2002) Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression. Ophthalmology 109: 1178–1182
Macarol V and Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118: 220–224
Zamir E et al. (2001) Self-inflicted anterior scleritis. Ophthalmology 108: 192–195
O'Donoghue E et al. (1992) Surgically induced necrotising sclerokeratitis (SINS)—precipitating factors and response to treatment. Br J Ophthalmol 76: 17–21
Dorey SE et al. (2002) Orbital lymphoma misdiagnosed as scleritis. Ophthalmology 109: 2347–2350
Yap EY et al. (1992) Scleritis as an initial manifestation of choroidal malignant melanoma. Ophthalmology 99: 1693–1697
Soukiasian SH et al. (1992) Diagnostic value of anti-neutrophil cytoplasmic antibodies in scleritis associated with Wegener's granulomatosis. Ophthalmology 99: 125–132
Hembry RM et al. (1979) Experimental model for scleritis. Arch Ophthalmol 97: 1337–1340
Fong LP et al. (1991) Immunopathology of scleritis. Ophthalmology 98: 472–479
Young RD and Watson PG (1984) Microscopical studies of necrotising scleritis. I. Cellular aspects. Br J Ophthalmol 68: 770–780
Rao NA et al. (1985) Necrotizing scleritis. A clinico-pathologic study of 41 cases. Ophthalmology 92: 1542–1549
Young RD and Watson PG (1984) Microscopical studies of necrotising scleritis. II. Collagen degradation in the scleral stroma. Br J Ophthalmol 68: 781–789
Di Girolamo N et al. (1997) Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol 150: 653–666
Riono WP et al. (1999) Scleritis: a clinicopathologic study of 55 cases. Ophthalmology 106: 1328–1333
Erhardt CC et al. (1989) Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 48: 7–13
Rosenbaum JT and Robertson JE Jr (1993) Recognition of posterior scleritis and its treatment with indomethacin. Retina 13: 17–21
Sainz de la Maza M et al. (1993) An analysis of therapeutic decision for scleritis. Ophthalmology 100: 1372–1376
Bauer AM et al. (2005) Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol 139: 1086–1089
Spiegel BM et al. (2005) Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 53: 185–197
Messmer EM and Foster CS (1995) Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea 14: 408–417
Kaplan-Messas A et al. (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11: 131–139
Shah SS et al. (1992) Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99: 1419–1423
Sen HN et al. (2003) Mycophenolate mofetil for the treatment of scleritis. Ophthalmology 110: 1750–1755
Thorne JE et al. (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112: 1472–1477
Hakin KN et al. (1991) Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Br J Ophthalmol 75: 340–341
Wakefield D and McCluskey P (1989) Cyclosporin therapy for severe scleritis. Br J Ophthalmol 73: 743–746
Langford CA et al. (2003) Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114: 463–469
Stone JH (2002) Polyarteritis nodosa. JAMA 288: 1632–1639
Albini TA et al. (2005) Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology 112: 1814–1820
Sen HN et al. (2005) Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis. Br J Ophthalmol 89: 917–918
Tu EY et al. (1995) Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection. Ophthalmology 102: 718–724
Smith JR et al. (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45: 252–257
El-Shabrawi Y and Hermann J (2005) Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 19: 1017–1018
Cazabon S et al. (2005) The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye 19: 222–224
Murphy CC et al. (2004) Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111: 352–356
Papaliodis GN et al. (2003) Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110: 786–789
Ahmadi-Simab K et al. (2005) Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 64: 1087–1088
Cheung CM et al. (2005) Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89: 1542
Acknowledgements
The authors are supported in part by Research to Prevent Blindness (Senior Scholar Award to JT Rosenbaum and Career Development Award to JR Smith) and the Rosenfeld Family Fund. The authors gratefully acknowledge Dr Narsing Rao, MD (Doheny Eye Institute, University of Southern California, Los Angeles), who provided the images in Figure 3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Smith receives support for clinical trials from Centocor and Allergan, with support from Abbott and Genentech currently pending. Dr Mackensen declared no competing interests. Dr Rosenbaum is a consultant for Novartis, Medarex and Bristol Myers. He receives support for clinical trials from Centocor and Allergan, with support from Abbott, Genentech and Amgen currently pending.
Rights and permissions
About this article
Cite this article
Smith, J., Mackensen, F. & Rosenbaum, J. Therapy Insight: scleritis and its relationship to systemic autoimmune disease. Nat Rev Rheumatol 3, 219–226 (2007). https://doi.org/10.1038/ncprheum0454
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0454